Table 1.
Demographic and disease characteristics of psoriasis patients with self-reported PsA in the PSOLAR registry: Overall population
| Ustekinumab (N = 628) | TNF inhibitorsa (N = 1413) | Infliximab (N = 258) | Etanercept (N = 481) | Adalimumab (N = 674) | Non-biologic /MTXb (N = 98) | Non-biologic /non-MTXc (N = 208) | Alld (N = 2401) | |
|---|---|---|---|---|---|---|---|---|
| Age, years | ||||||||
| Mean ± SD | 49.7 ± 12.6 | 50.4 ± 12.5 | 49.5 ± 12.6 | 51.1 ± 13.0 | 50.4 ± 12.0 | 55.6 ± 12.3 | 53.4 ± 14.3 | 50.8 ± 12.8 |
| Sex | ||||||||
| Men | 352 (56.1) | 757 (53.6) | 138 (53.5) | 259 (53.8) | 360 (53.4) | 34 (34.7) | 99 (47.6) | 1272 (53.0) |
| Race | ||||||||
| White | 527 (83.9) | 1157 (81.9) | 223 (86.4) | 392 (81.5) | 542 (80.4) | 80 (81.6) | 190 (91.3) | 2000 (83.3) |
| Body mass index (BMI) (kg/m2) | ||||||||
| N | 617 | 1372 | 245 | 471 | 656 | 93 | 203 | 2339 |
| Mean ± SD | 32.1 ± 7.0 | 31.7 ± 7.4 | 32.9 ± 8.4 | 31.1 ± 7.3 | 31.7 ± 7.1 | 30.8 ± 7.3 | 30.6 ± 6.9 | 31.7 ± 7.2 |
| Obesity class | ||||||||
| N | 617 | 1372 | 245 | 471 | 656 | 93 | 203 | 2339 |
| Underweight-normal (BMI < 18.5–24.9) | 80 (13.0) | 209 (15.2) | 29 (11.8) | 81 (17.2) | 99 (15.1) | 24 (25.8) | 41 (20.2) | 359 (15.3) |
| Overweight-obesity class I (25.0–34.9) | 353 (57.2) | 779 (56.8) | 136 (55.5) | 268 (56.9) | 375 (57.2) | 43 (46.2) | 110 (54.2) | 1315 (56.2) |
| Obesity class II-III (35.0- ≥40) | 184 (29.8) | 384 (28.0) | 80 (32.7) | 122 (25.9) | 182 (27.7) | 26 (28.0) | 52 (25.6) | 665 (28.4) |
| Psoriasis disease characteristics | ||||||||
| Duration of psoriasis, years | ||||||||
| N | 627 | 1400 | 256 | 477 | 667 | 97 | 208 | 2385 |
| Mean ± SD | 20.8 ± 13.0 | 19.0 ± 13.4 | 20.1 ± 13.8 | 18.0 ± 13.6 | 19.3 ± 13.2 | 17.4 ± 13.5 | 17.5 ± 15.4 | 19.3 ± 13.6 |
| BSA involvement (%) | ||||||||
| N | 616 | 1383 | 247 | 472 | 664 | 96 | 205 | 2353 |
| Median | 6.0 | 4.0 | 4.0 | 3.8 | 4.0 | 6.0 | 8.0 | 5.0 |
| Baseline PGA score | ||||||||
| N | 618 | 1386 | 249 | 474 | 663 | 96 | 205 | 2359 |
| Mean ± SD | 2.3 ± 1.2 | 1.9 ± 1.2 | 1.9 ± 1.2 | 1.9 ± 1.2 | 2.0 ± 1.3 | 2.4 ± 1.1 | 2.5 ± 1.1 | 2.1 ± 1.2 |
| Medical historye | ||||||||
| PsA | 628 (100.0) | 1413 (100.0) | 258 (100.0) | 481 (100.0) | 674 (100.0) | 98 (100.0) | 208 (100.0) | 2401 (100.0) |
| Cardiovascular disease | 272 (43.3) | 605 (42.8) | 121 (46.9) | 214 (44.5) | 270 (40.1) | 43 (43.9) | 100 (48.1) | 1040 (43.3) |
| Psychiatric illness | 158 (25.2) | 344 (24.3) | 69 (26.7) | 117 (24.3) | 158 (23.4) | 21 (21.4) | 49 (23.6) | 584 (24.3) |
| Anxiety | 84 (13.4) | 196 (13.9) | 40 (15.5) | 69 (14.3) | 87 (12.9) | 10 (10.2) | 31 (14.9) | 327 (13.6) |
| Depression | 116 (18.5) | 236 (16.7) | 46 (17.8) | 78 (16.2) | 112 (16.6) | 14 (14.3) | 36 (17.3) | 413 (17.2) |
| Inflammatory bowel disease | 16 (2.5) | 37 (2.6) | 8 (3.1) | 11 (2.3) | 18 (2.7) | 4 (4.1) | 5 (2.4) | 64 (2.7) |
| Crohn’s disease | 4 (0.6) | 9 (0.6) | 2 (0.8) | 3 (0.6) | 4 (0.6) | 1 (1.0) | 1 (0.5) | 16 (0.7) |
| Ulcerative colitis | 3 (0.5) | 10 (0.7) | 2 (0.8) | 2 (0.4) | 6 (0.9) | 1 (1.0) | 1 (0.5) | 15 (0.6) |
| Indeterminate colitis | 6 (1.0) | 15 (1.1) | 4 (1.6) | 5 (1.0) | 6 (0.9) | 2 (2.0) | 3 (1.4) | 26 (1.1) |
| Pulmonaryf | 94 (15.0) | 225 (15.9) | 40 (15.5) | 76 (15.8) | 109 (16.2) | 21 (21.4) | 46 (22.1) | 395 (16.5) |
| Hepatic | 22 (3.5) | 56 (4.0) | 14 (5.4) | 19 (4.0) | 23 (3.4) | 2 (2.0) | 9 (4.3) | 92 (3.8) |
| Skin cancer | 28 (4.5) | 88 (6.2) | 14 (5.4) | 38 (7.9) | 36 (5.3) | 6 (6.1) | 15 (7.2) | 144 (6.0) |
| Other cancers | 17 (2.7) | 48 (3.4) | 9 (3.5) | 18 (3.7) | 21 (3.1) | 13 (13.3) | 14 (6.7) | 95 (4.0) |
| Endocrine | 135 (21.5) | 315 (22.3) | 60 (23.3) | 113 (23.5) | 142 (21.1) | 26 (26.5) | 52 (25.0) | 539 (22.4) |
| Diabetes mellitus type I | 8 (1.3) | 23 (1.6) | 6 (2.3) | 10 (2.1) | 7 (1.0) | 1 (1.0) | 7 (3.4) | 39 (1.6) |
| Diabetes mellitus type II | 90 (14.3) | 181 (12.8) | 35 (13.6) | 62 (12.9) | 84 (12.5) | 15 (15.3) | 33 (15.9) | 325 (13.5) |
| Thyroid dysfunction | 46 (7.3) | 134 (9.5) | 25 (9.7) | 47 (9.8) | 62 (9.2) | 13 (13.3) | 18 (8.7) | 218 (9.1) |
| History of infectionsg | 167 (26.6) | 388 (27.5) | 84 (32.6) | 137 (28.5) | 167 (24.8) | 23 (23.5) | 43 (20.7) | 641 (26.7) |
| Social activitye | ||||||||
| Alcohol use, N | 628 | 1413 | 258 | 481 | 674 | 98 | 208 | 2401 |
| Never used | 130 (20.7) | 301 (21.3) | 70 (27.1) | 91 (18.9) | 140 (20.8) | 47 (48.0) | 55 (26.4) | 545 (22.7) |
| Current user | 426 (67.8) | 905 (64.0) | 161 (62.4) | 302 (62.8) | 442 (65.6) | 35 (35.7) | 120 (57.7) | 1521 (63.3) |
| Have used and stopped | 72 (11.5) | 207 (14.6) | 27 (10.5) | 88 (18.3) | 92 (13.6) | 16 (16.3) | 33 (15.9) | 335 (14.0) |
| Smoking, N | 628 | 1412 | 257 | 481 | 674 | 98 | 208 | 2400 |
| Never smoked | 256 (40.8) | 651 (46.1) | 122 (47.5) | 220 (45.7) | 309 (45.8) | 47 (48.0) | 85 (40.9) | 1059 (44.1) |
| Current smoker | 147 (23.4) | 287 (20.3) | 61 (23.7) | 85 (17.7) | 141 (20.9) | 24 (24.5) | 53 (25.5) | 521 (21.7) |
| Prior smoker, stopped | 225 (35.8) | 474 (33.6) | 74 (28.8) | 176 (36.6) | 224 (33.2) | 27 (27.6) | 70 (33.7) | 820 (34.2) |
Data are n (%) unless otherwise indicated
The biologic user cohort includes patients who are on the cohort defining biologic at entry or start the biologic after entry; previous use or current exposure is allowed for MTX, but not for other systemic immunomodulators
BMI body mass index; BSA body surface area; MTX methotrexate; PGA Physician’s Global Assessment; PsA psoriatic arthritis; PSOLAR Psoriasis Longitudinal Assessment and Registry; SD standard deviation
aTumor necrosis factor (TNF) inhibitors include infliximab, etanercept, and adalimumab
b The non-biologic/MTX cohort includes patients who are on methotrexate at entry or start methotrexate during the registry and haven’t been exposed to other systemic immunomodulators previously or concurrently
cNon-biologic, non-MTX therapies may include, but are not limited to, cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine, oral corticosteroids, systemic retinoids, psoralen plus ultraviolet (UV), or UVB phototherapy. The non-biologic/non-MTX cohort includes patients who are on other systemic immunomodulators (including cyclosporine, tacrolimus, mycophenolate mofetil, other immunomodulators, and oral corticosteroids) at entry or start other immunomodulators after registry and who haven’t been exposed to MTX previously or concurrently; patients who are on or receive only topical and/or phototherapy at/after registry entry are also in this cohort
dIncludes “Other biologics” group (n = 54); data not shown
eData were collected at baseline (defined as the last non-missing value that is closest and prior to/on the cohort start date)
fIncludes sleep apnea, asthma, chronic obstructive pulmonary disorder, and pneumonitis
gHistory of infections is defined as infections within 3 years of enrollment and required a prescription medication
Obesity class based upon National Heart Lung and Blood Institute Obesity Education Initiative http://www.nhlbi.nih.gov/health/public/heart/obesity/lose_wt/bmi_dis.html